- Home
- LRMR vs URGN Comparison
LRMR vs URGN Comparison
Compare LRMR & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- URGN
- Stock Information
- Founded
- LRMR N/A
- URGN 2004
- Country
- LRMR United States
- URGN United States
- Employees
- LRMR N/A
- URGN N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- LRMR Health Care
- URGN Health Care
- Exchange
- LRMR Nasdaq
- URGN Nasdaq
- Market Cap
- LRMR 426.9M
- URGN 465.9M
- IPO Year
- LRMR N/A
- URGN 2017
- Fundamental
- Price
- LRMR $3.34
- URGN $10.27
- Analyst Decision
- LRMR Strong Buy
- URGN Strong Buy
- Analyst Count
- LRMR 8
- URGN 5
- Target Price
- LRMR $19.63
- URGN $44.50
- AVG Volume (30 Days)
- LRMR 678.8K
- URGN 487.3K
- Earning Date
- LRMR 03-13-2025
- URGN 03-13-2025
- Dividend Yield
- LRMR N/A
- URGN N/A
- EPS Growth
- LRMR N/A
- URGN N/A
- EPS
- LRMR N/A
- URGN N/A
- Revenue
- LRMR N/A
- URGN $89,363,000.00
- Revenue This Year
- LRMR N/A
- URGN $13.39
- Revenue Next Year
- LRMR N/A
- URGN $45.06
- P/E Ratio
- LRMR N/A
- URGN N/A
- Revenue Growth
- LRMR N/A
- URGN 15.64
- 52 Week Low
- LRMR $3.01
- URGN $9.78
- 52 Week High
- LRMR $13.68
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- LRMR 29.00
- URGN 39.53
- Support Level
- LRMR $3.24
- URGN $10.12
- Resistance Level
- LRMR $3.54
- URGN $10.96
- Average True Range (ATR)
- LRMR 0.22
- URGN 0.57
- MACD
- LRMR 0.03
- URGN -0.01
- Stochastic Oscillator
- LRMR 12.26
- URGN 24.75
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.